Brief: Hemostemix Announces Submission Of Orphan Drug Designation Application To The FDA
04/02/2019 13:40
Feb 4 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX ANNOUNCES SUBMISSION OF ORPHAN DRUG DESIGNATION
APPLICATION TO THE FDA
Source text for Eikon: ID:nGNX84rZLf
Further company coverage: HEM.V
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update